The world health organization has identified high blood pressure (BP) as one of the most important modifiable risk factors to reduce rapidly escalating burden of cardiovascular (CV) disease. Globally, 13.5% of total premature deaths annually (i.e.7.6 million deaths) are directly attributed to hypertension. Randomised clinical trial data are consistent in showing that BP reduction substantially reduces cardiovascular morbidity and mortality. However, despite these facts and widespread availability of effective antihypertensive medications, the vast majority of more than 1 billion hypertensive patients remain with uncontrolled BP. Even among hypertensive patients who receive treatment, in most countries at least half of them fail to reach currently recommended BP targets.